MOTS-c

Dosing from the Literature

Published for longevity: mouse doses only, 0.5 mg/kg a day against diet-induced obesity (Lee et al., 2015) and 15 mg/kg in aging mice (Reynolds et al., 2021). Not published: any human dose; the 5–10 mg injections in user reports and clinic protocols come from no study.

No trial or label gives a human dose of MOTS-c. The human figures below are what user reports, an online guide and one clinic describe; they agree on 5–10 mg per injection but not on how often or for how long, and no published study has tested any of them. The mouse figures come from the studies cited.

What It Is

MOTS-c (pronounced "mots-see") stands for "Mitochondrial Open Reading Frame of the Twelve S rRNA, type c." It is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded by a small open reading frame within the mitochondrial 12S ribosomal RNA gene. Its discovery in 2015 by Changhan "David" Lee, Pinchas Cohen, and colleagues at the USC Leonard Davis School of Gerontology was a landmark finding for a conceptual reason as much as a therapeutic one: MOTS-c was among the first mitochondrial-derived peptides (MDPs) demonstrated to have systemic endocrine-like hormonal effects. Mitochondrial DNA had been understood to encode only a handful of proteins involved in local oxidative phosphorylation; MOTS-c extended the mitochondrial genome's role into peripheral metabolic signaling.

The mechanism-defining paper — Lee et al., Cell Metabolism 2015 (PMID 25738459) — demonstrated that MOTS-c regulates insulin sensitivity and metabolic homeostasis via AMPK activation mediated through inhibition of the folate cycle and de novo purine biosynthesis. That AMPK-activation framework places MOTS-c in the same functional category as metformin, AICAR, and caloric restriction — all of which converge on AMPK as a metabolic "energy sensor" that shifts cells toward fat oxidation, glucose uptake, and mitochondrial biogenesis.

The second landmark finding came in 2021 with Reynolds et al. in Nature Communications (PMID 33473109), showing that MOTS-c is induced by exercise in skeletal muscle and in circulation, and that exogenous MOTS-c administration improves age-dependent physical decline and muscle homeostasis in mice. Mice of all ages receiving MOTS-c injections performed significantly better than untreated controls on rotarod balance and treadmill endurance tests. This framing of MOTS-c as an "exercise-induced exercise mimetic" became the dominant narrative for the peptide in community and commercial contexts, alongside its insulin-sensitizing metabolic profile.

As of April 2026, there are no published Phase 2 or Phase 3 human randomized controlled trials for exogenous MOTS-c in any indication. The evidence base is rich preclinical data (mouse insulin sensitivity, muscle endurance, obesity, age-related physical decline) plus a growing observational human literature correlating endogenous MOTS-c levels with exercise response, insulin sensitivity, and age. Exogenous use in the community context is extrapolation from the preclinical framework, not from validated human outcomes.

Mechanism of Action

In cell and mouse studies, MOTS-c acts partly through AMPK (Lee et al., 2015) and by moving into the nucleus to regulate genes under metabolic stress (Kim et al., Cell Metab 2018); in mice it improved insulin sensitivity and physical performance (Lee et al., 2015; Reynolds et al., 2021).

• AMPK activation via folate-cycle inhibition — In cultured human cells, MOTS-c depleted 5-methyl-tetrahydrofolate, the main active form of folate, and blocked the de novo purine synthesis tied to it; the purine intermediate AICAR (aminoimidazole carboxamide ribonucleotide) built up and AMPK was activated. Blocking AMPK cut MOTS-c's boost to glycolysis by 16–40%, so AMPK carries part of the effect, not all of it (Lee et al., 2015).
• Skeletal muscle glucose uptake — In mice, a 7-day course raised insulin-stimulated glucose disposal into muscle, and in mice on a high-fat diet it raised AMPK activation and GLUT4 levels in muscle (Lee et al., 2015).
• Insulin sensitization — Mice given MOTS-c showed improved insulin sensitivity and protection against high-fat-diet-induced insulin resistance, and 7 days of treatment restored muscle insulin sensitivity in 12-month-old mice to young levels. Its main target appears to be skeletal muscle, which takes up 70–85% of insulin-stimulated glucose (Lee et al., 2015).
• Mitochondrial biogenesis — A review states that MOTS-c leads to mitochondrial biogenesis (Mohtashami et al., 2022), but the primary studies cited here do not show it in muscle. In ovariectomized mice MOTS-c activated brown fat (Lu et al., 2019), and a commentary on that study suggests it changes mitochondrial number and function there (Kim et al., 2019).
• Fuel use and fat — MOTS-c reduced fat gain in mice on a high-fat diet without lowering food intake (Lee et al., 2015; Reynolds et al., 2021). Which fuel it shifts toward differs by model: those high-fat-fed mice burned relatively more glucose (Lee et al., 2015), while old mice burned relatively more fat and mouse muscle cells used more fatty acid (Reynolds et al., 2021).
• Exercise mimicry — Reynolds 2021 demonstrated that MOTS-c is induced by exercise in humans: one cycling session raised it 11.9-fold in muscle and about 1.5-fold in plasma in 10 young men. Injected MOTS-c improved treadmill running in young, middle-aged and old mice (Reynolds et al., 2021).
• Inflammation — Findings point both ways. In mice, 4 days of injections lowered circulating IL-6 and TNF-α (Lee et al., 2015), and MOTS-c reduced inflammatory cell invasion of white fat after ovariectomy (Lu et al., 2019). In senescent human fibroblasts, it modestly raised some of the inflammatory factors they secrete (Kim et al., Aging 2018).
• Nuclear translocation (unusual feature) — In cultured human cells, MOTS-c moved from the mitochondria into the nucleus within 30 minutes of glucose restriction, serum deprivation or oxidative stress, depending on AMPK, and bound the promoters of antioxidant-response genes (Kim et al., Cell Metab 2018). Its authors note that no factor encoded in mitochondrial DNA had been known to move to the nucleus (Kim et al., Cell Metab 2018).
• Bone metabolism — A review summarizes lab and mouse work: MOTS-c raised type I collagen production in human osteoblast cells and reduced bone loss in ovariectomized mice by suppressing osteoclast formation (Mohtashami et al., 2022).
• Brain — In mice, regular exercise raised MOTS-c in hypothalamic POMC neurons, where it drove POMC gene activity (Kong et al., 2023). No study cited here shows that injected MOTS-c crosses the blood-brain barrier.

What the Research Shows

MOTS-c has an unusually rigorous preclinical evidence base for a community peptide, concentrated in the Lee/Cohen USC lab and independent replication groups.

• Discovery and metabolic characterization (Lee et al., Cell Metabolism 2015; PMID 25738459) — Foundational paper. Identified MOTS-c as mitochondrial-12S-rRNA-encoded, demonstrated AMPK-mediated insulin sensitization, prevented diet-induced insulin resistance in mice.
• Exercise-induced regulation (Reynolds et al., Nat Commun 2021; PMID 33473109) — Demonstrated MOTS-c is exercise-induced in skeletal muscle and circulation; exogenous MOTS-c restored age-dependent physical capacity in 2, 12, and 22-month-old mice.
• Insulin sensitizer commentary (Kim et al., 2019; PMC6462348) — "MOTS-c: an equal opportunity insulin sensitizer", written on Lu et al.'s finding in ovariectomized female mice and characterizing its broad effect across metabolic tissue types.
• Aging / age-related disease review (Mohtashami et al., 2022; PMID 36233287) — Modern comprehensive review of MOTS-c in aging and age-related diseases.
• Mitochondrial-derived peptides comprehensive review (Miller et al., Exp Cell Res 2020) — Placed MOTS-c in the broader MDP family (Humanin, SHLP1-6, MOTS-c) and mitochondrial-nuclear communication framework.
• Nuclear translocation under stress (Kim et al., Cell Metab 2018) — Established that MOTS-c translocates from mitochondria to nucleus under metabolic stress to regulate adaptive gene expression.
• Endurance and aging (Reynolds 2021 continuation) — In the flagship 2021 paper, MOTS-c more than doubled treadmill running capacity in untrained sedentary old mice — the specific data point that put "exercise protein" in the popular press.
• Exercise response in rodents (Hyatt, Physiol Rep 2022) — 4–8 weeks of voluntary running raised MOTS-c about 1.5–5-fold in rodent leg muscles, and a single 15 mg/kg dose raised running time by 12% and distance by 15% in untrained mice.
• Ethnicity / breast cancer survivors — Effect of aerobic and resistance exercise on MOTS-c in Hispanic and non-Hispanic White breast cancer survivors (Sci Rep 2021) — documenting MOTS-c's responsiveness in human populations.
• Bone density / osteoporosis models — Preclinical data showing MOTS-c preserves bone mineral density in aged and ovariectomized mouse models.
• Cardiovascular / heart failure models — Preclinical protection against ischemia-reperfusion injury and cardiac hypertrophy.
• Adipose tissue metabolic modulation — Reduces adiposity, improves leptin sensitivity, increases brown adipose-like thermogenic activity in some models.
• Neuroprotection (Alzheimer's models) — Preclinical data showing reduced amyloid plaque burden and improved cognitive function in AD mouse models.

Human Data

Human data is primarily observational — correlating endogenous MOTS-c levels with physiology — rather than interventional exogenous MOTS-c administration:

• Age-related decline (observational, multiple studies) — Plasma MOTS-c declines with age in humans, paralleling mitochondrial function decline.
• Exercise-induced elevation (Reynolds 2021; Hyatt 2022) — One cycling session raised MOTS-c in the muscle and plasma of 10 young men (Reynolds et al., 2021); in rodents, weeks of voluntary running raised it in muscle (Hyatt, 2022).
• Insulin resistance correlation — Lower circulating MOTS-c in insulin-resistant and type 2 diabetic humans vs healthy controls.
• Breast cancer survivor exercise study (Sci Rep 2021) — Documents MOTS-c responsiveness to aerobic and resistance exercise in human cancer survivor population.
• Coronary artery disease correlation — Lower MOTS-c in patients with CAD; association is observational, not interventional.
• Menopause / sex differences — Differential MOTS-c in pre- vs post-menopausal women; observational.
• Community user reports — Anecdotal reports of improved endurance, insulin sensitivity, body composition on exogenous MOTS-c protocols; no validated outcome measures.
• No published Phase 2 or Phase 3 RCT — As of October 2026, no human trial of injected MOTS-c has been published. This is the central evidence gap.

The situation parallels early NAD+ precursor research: strong mechanistic preclinical data, observational human biomarker correlation, but the decisive randomized controlled trial of exogenous administration lagging the commercial/community use. Over the next several years, published human MOTS-c RCT data will either confirm the mechanism translates to humans or force recalibration.

Reconstitution & Storage

An online guide and one clinic describe MOTS-c as a freeze-dried (lyophilized) powder in 10 mg vials.

• Reconstitution — An online guide describes letting the bacteriostatic water trickle slowly down the vial wall and swirling gently rather than shaking, until the solution is clear; one clinic's protocol also describes a gentle swirl.
• Storage — For the unmixed powder, one guide lists −20°C and another −20°C to 4°C. After mixing, guides and one clinic list 2–8°C, with use-by times from 14 to 30 days, and one guide says not to freeze the mixed solution.
• Injection sites — A clinic's patient guide describes injecting under the skin of the abdomen or thigh with a small insulin needle, rotating the site daily.
• Timing — Sources disagree. Online guides describe morning or pre-exercise injections (one lists 30–60 minutes before training); one clinic's protocol uses the morning before the first meal; user reports also describe injecting within an hour after a workout. No study has compared them.
• Inspection — An online guide describes discarding a mixed solution that turns cloudy or discolored.

→ Calculator — vial-to-syringe math

Side Effects & Risks

There are no human safety data. The lines below come from a clinic's patient guide, online guides, user reports and lab studies; the mouse studies cited here were not designed to test safety.

• Injection site reactions — A clinic's patient guide lists brief injection-site reactions, and user reports describe redness and transient swelling.
• Fatigue / initial lethargy — A clinic's patient guide and an online guide list mild fatigue in the first week, and user reports describe occasional early fatigue.
• Hypoglycemia risk (theoretical) — In mice, MOTS-c modestly lowered blood glucose and improved insulin sensitivity (Lee et al., 2015), so in theory it could add to the effect of insulin or insulin secretagogues. No study has tested the combination; an online guide lists blood-sugar fluctuations in users who inject while fasting.
• GI discomfort — An online guide lists occasional nausea; a clinic's patient guide lists mild gastrointestinal changes as rare, usually resolving within the first week.
• Appetite — No human study. In mice, food intake fell over 4 days of injections (Lee et al., 2015) and over late-life treatment (Reynolds et al., 2021), but was unchanged in mice on a high-fat diet (Lee et al., 2015; Reynolds et al., 2021).
• Cancer caveat (theoretical) — None of the studies cited here gave MOTS-c in a cancer model. In culture it slowed the growth of human kidney cells made to overproduce it (Lee et al., 2015) but sped the regrowth of mouse muscle cells after metabolic stress (Reynolds et al., 2021), so which way it would push a tumor is unknown.
• Autoimmune considerations — MOTS-c does act on the immune system in mice: it delayed autoimmune (type 1) diabetes in NOD mice and damped T-cell activation (Kong et al., 2023). No study has given it to people with autoimmune disease.
• Drug interactions — No study cited here tested MOTS-c together with another drug, and there are no human interaction data. Metformin also activates AMPK (Lee et al., 2015), so additive glucose lowering with diabetes drugs is a theoretical concern.
• Pregnancy / lactation — No study has given MOTS-c to pregnant or breastfeeding women.
• Purity / sourcing — Sold as a research chemical, not an approved drug, so no FDA review covers its purity.
• WADA status — Named on the 2026 Prohibited List in section S4.4.1, among activators of AMP-activated protein kinase, as “mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)”: prohibited at all times, in and out of competition, and non-specified (World Anti-Doping Agency, 2026).
• FDA status — Not approved; not a controlled substance. Gray-market research-chemical supply.

Supportive Nutrition & Supplements

• Folate — In cultured human cells, adding folic acid reversed MOTS-c's effects on glucose use and oxygen consumption (Lee et al., 2015); whether folate intake matters in people is untested.

What to Expect — Timeline

Quick Compare — MOTS-c vs SS-31 vs NAD+ vs Humanin

MOTS-c sits in the "mitochondrial peptide / mitochondrial optimization" category. The most relevant comparators are other mitochondrial-targeting compounds — SS-31 (cardiolipin-binding), NAD+ precursors (substrate supply), and Humanin (another mitochondrial-derived peptide).

Practical interpretation:

• MOTS-c vs SS-31 — Different mitochondrial targets. MOTS-c activates AMPK systemically; SS-31 binds cardiolipin and stabilizes inner mitochondrial membrane. Complementary rather than substitutive.
• MOTS-c vs NAD+ — MOTS-c activates metabolic pathways; NAD+ provides substrate. One clinic calls MOTS-c plus NAD+ one of its most common longevity-focused stacks; no study has tested the pair.
• MOTS-c vs Humanin — Both mitochondrial-derived peptides. Humanin is more CNS-focused with documented neuroprotective effects; MOTS-c is more metabolic/peripheral. Combined "MDP stack" is community speculation rather than trial-validated.
• Evidence maturity — SS-31 is the only FDA-approved compound in this comparison (as Forzinity, for Barth syndrome, 2025). NAD+ precursors have the deepest supplement-level RCT base. MOTS-c has the strongest preclinical mechanistic evidence but thinnest human RCT data. Humanin is the least-developed clinically.

→ See full SS-31 profile  •  → See NAD+ profile  •  → See Humanin profile

Practical User Notes

• Combined with training — In old mice, MOTS-c changed muscle metabolism after a treadmill run but not in mice that had not exercised (Reynolds et al., 2021); no human study has tested it with or without training.
• Pre-training or morning dosing — Online guides describe morning or pre-exercise injections (one lists 30–60 minutes before training). No human study has measured how long MOTS-c lasts in the body.
• Diabetes medications — In theory MOTS-c could add to the glucose-lowering effect of insulin or insulin secretagogues, since it lowered blood glucose in mice (Lee et al., 2015); no study has tested the combination. Consult a licensed healthcare provider.
• Other AMPK activators — Taking MOTS-c with other AMPK activators, such as metformin or AICAR, is unstudied.
• Injection technique — A clinic's patient guide describes a small insulin needle, under the skin of the abdomen or thigh, with the site rotated daily.
• Storage — After mixing, guides and one clinic list 2–8°C, with use-by times from 14 to 30 days.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for MOTS-c. One clinic's patient guide describes periodic fasting glucose, IGF-1 and lipid tests for long-term use.

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching MOTS-c often also look at these:

Next Steps

References

1. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009.
2. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109. DOI: 10.1038/s41467-020-20790-0.
3. Kim SJ, Miller B, Kumagai H, Yen K, Cohen P. MOTS-c: an equal opportunity insulin sensitizer. J Mol Med (Berl). 2019;97(4):487-490. PMC6462348.
4. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246.
5. Miller B, Kim SJ, Kumagai H, Mehta HH, Xiang W, Liu J, Yen K, Cohen P. Peptides derived from small mitochondrial open reading frames: Genomic, biochemical, and physiological features. Exp Cell Res. 2020;393(2):112057.
6. Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022;23(19):11991. PMID: 36233287.
7. Hyatt JK. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose. Physiol Rep. 2022;10(10):e15377. PMID: 35808870.
8. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019;97(4):473-485. PMID: 30725119.
9. Mendelsohn AR, Larrick JW. Mitochondrial-Derived Peptides Exacerbate Senescence. Rejuvenation Res. 2018;21(4):369-373. PMID: 30058454.
10. Yin X, Jing Y, Chen Q, et al. The intraocular expression of MOTS-c in patients with age-related cataracts: Correlation between MOTS-c and lens mitochondrial DNA levels. Clin Exp Ophthalmol. 2022;50(5):498-506.
11. Zempo H, Kim SJ, Fuku N, et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY). 2021;13(2):1692-1717. PMID: 33468709.
12. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66(6):1019-1022. PMID: 29593067.
13. Kong BS, Lee C, Cho YM. Mitochondrial-encoded peptide MOTS-c, diabetes, and aging-related diseases. Diabetes Metab J. 2023;47(3):315-327. PMID: 36824008.
14. Yang B, Yu Q, Chang B, Guo Q, Xu S, Yi X, Cao S. MOTS-c interacts with mitochondrial proteins and exercise-induced adaptation. Biochem Biophys Res Commun. 2021;534:468-474.
15. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. Sci Rep. 2021;11(1):16916. PMID: 34413391.
16. Woodhead JST, D'Souza RF, Hedges CP, et al. High-intensity interval exercise increases humanin, a mitochondrial encoded peptide, in the plasma and muscle of men. J Appl Physiol. 2020;128(5):1346-1354. PMID: 32271093.
17. Lee C, Yen K, Cohen P. Humanin: a harbinger of mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24(5):222-228. PMID: 23402768.
18. Kim SJ, Mehta HH, Wan J, Kuehnemann C, Chen J, Hu JF, Hoffman AR, Cohen P. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY). 2018;10(6):1239-1256. PMID: 29886458.
19. Yen K, Mehta HH, Kim SJ, et al. The mitochondrial derived peptide Humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(12):11185-11199. PMID: 32575074.
20. Yin Y, Pan Y, He J, Zhong H, Wu Y, Ji C, Liu L, Cui X. The mitochondrial-derived peptide MOTS-c promotes adipose tissue aging via inducing senescence of preadipocytes. Front Endocrinol. 2023;14:1120533. (Noting a published caveat — MDPs may have pro-senescence effects in some contexts.)
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S4.4.1, activators of the AMP-activated protein kinase (AMPK). wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 5, 2026.
23. World Anti-Doping Agency. Prohibited List 2027 (in effect January 1, 2027), French edition with track changes, August 26, 2026, and Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List, August 17, 2026: wada-ama.org/sites/default/files/2026-09/2027list_final_fr_track_changes_26_august_2026.pdf and 2027_list_explanatory_note_en_final_17_august_2026_1.pdf, read October 12, 2026 in the Internet Archive’s copies captured October 9, 2026 (web.archive.org). The List’s English edition was not available there and was not read.

Related Research

• AICARAMPK Activator / Exercise Mimetic
• SLU-PP-332ERR Pan-Agonist / Exercise Mimetic
• HumaninMitochondrial-Derived Peptide (MDP)
• ArgirelineSNAP-25 Mimetic
• Mito StackMOTS-c · NAD+ · SS-31 — mitochondrial support protocol
• FDA TrackerMOTS-c was removed from Category 2 on April 22, 2026 (FDA notice April 15, 2026). PCAC recommended it on July 23–24, 2026. Rulemaking pending — not legal to compound today.
• CardarineGW501516 · PPARδ Agonist (WADA S4.4.1, with MOTS-c)
• KlothoAging-Suppressor Protein / FGF23 Co-Receptor